Update shared on 13 Nov 2025
Fair value Increased 5.03%Analysts have raised Biocon's fair value price target from ₹376.70 to ₹395.65, citing improved revenue growth projections and profit margins as key drivers for the upgrade.
What's in the News
- Biocon announced the public funding of YESAFILI (aflibercept), a biosimilar to EYLEA, on the Ontario Drug Benefit Formulary in Canada for retinal disease treatment. This development is expected to improve patient access to care (Key Developments).
- The company inaugurated its first U.S. manufacturing facility in Cranbury, New Jersey, which enables diversification of its manufacturing base and helps accelerate global expansion. The facility has an annual capacity of 2 billion tablets (Key Developments).
- Biocon and Equillium terminated their collaboration and license agreement for itolizumab after Equillium decided not to continue development of the product (Key Developments).
- Recent board meetings have addressed financial results for the latest quarter, approved early redemption of Non-Convertible Debentures, and appointed a new Company Secretary and Compliance Officer (Key Developments).
Valuation Changes
- The consensus analyst price target has increased from ₹376.70 to ₹395.65, reflecting higher valuation expectations.
- The discount rate has decreased slightly from 13.67% to 13.55%.
- The revenue growth forecast has risen from 15.17% to 18.03%.
- The net profit margin estimate has improved from 8.79% to 9.17%.
- The future P/E multiple has increased from 29.81x to 35.70x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.